China Molecular Diagnostics & Database Package
| Publication Date | January 2008 |
|---|---|
| Publisher | General Biologic |
| Product Type | Report |
| Pages | 80 |
| ISBN Number | not applicable |
| Product Code | GBI00006 |
Summary
China Molecular diagnostics in a high growth, high profit, high investment area in China. Industry players, investors, buyers, and vendors will benefit from this essential database. This database includes more than 100 companies providing molecular diagnostic products and services in China. More than 50 Chinese domestic and multinational kit & instrument manufacturers are included. The database also includes key distributors and service providers.
Method of information collection: secondary research targeting company domain, public domain and government resources was conducted. This was followed by a primary phase including contact of more than 60% of companies in the database, and discussions with industry insiders.
China Molecular Disgnostic database includes more than 100 companies providing molecular diagnostic products and services in China. More than 50 Chinese domestic and multinational kit & instrument manufacturers are included. The database also includes key distributors and service providers. The database is searchable entries include:
- I. Company name in English
- II. Company name in Chinese
- III. Address, phone number, and fax number
- VI. Website and e-mail
- V. Company products with SFDA licenses
- VI. Additional key products
- VII. Relevant awards and certificates such as China GMP, ISO
- VIII. Ownership structure
- IX. Main products and services
- X. Founding year (90%)
- XI. Company introduction (60%)
Content
- Executive summary
- I. History of molecular diagnostics in China
- II. Polymerase chain reaction (PCR) technologies
- III. Biochips
- IV. Other molecular diagnostic technologies
- V. Key molecular markers and indicators
- VI. Government & policy environment
- VII. Market
- VIII. Profiles
About this Product
Delivery Details
PDF:Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
Related Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















